Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
IOME BIO logo — Harnessing unique, proprietary microbiome insights to unlock...

IOME BIO

Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology

Founded 2020 France France 4 employees Biotechnology, Health Care +1

General Information

Company Name IOME BIO
Founded Year 2020
Location France France
Employees 4
Industries Biotechnology, Health Care, Life Sciences
Social

BounceWatch is an independent company data service, not affiliated with IOME BIO. To contact IOME BIO, visit iomebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does IOME BIO compare?

A PDF of IOME BIO and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting IOME BIO soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About IOME BIO

Iome Bio is a biotechnology company based in France, founded in 2020. The company is focused on harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology. With a slogan of "Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology," Iome Bio aims to address the challenge of low response rates to current cancer treatments, particularly PD/L-1 therapies. The company's differentiated approach involves targeting the microbiome's downstream mode of action, enabling signal amplification through first-in-class monoclonal antibodies. This approach sets Iome Bio apart from other companies in the field, which mostly focus on T-cells or the tumor microenvironment. The company's strategy aligns with the growing evidence that patients with healthier microbiomes respond better to immuno-oncology therapies. Considering the significant unmet need in cancer treatment and the promising clinical data related to enhancing the microbiome, Iome Bio's approach holds potential. While the company has not disclosed its last investment or investors, the innovative nature of its approach and the pressing demand for improved cancer therapies position Iome Bio as a compelling prospect for future investment and a noteworthy player in the biotechnology and healthcare industries.

Business keywords: microbiome insights, immuno-oncology, PD/L-1 therapies, cancer treatment, R&D programs, live biotherapeutics, monoclonal antibodies, French biotech company, immuno-oncology drugs, checkpoint inhibitors, tumor microenvironment, drug resistance, Harvard laboratories, first in class, clinical data

No funding data available for IOME BIO yet.

IOME BIO Alternatives & Competitors

View All Alternatives
IOME BIO vs
Farcast Biosciences
Farcast Biosciences India

24,000 human tumors and counting - building the most precise functional precision tumor microdynamic...

Pre-Seed
38 employees
Biotechnology, Health Care
IOME BIO vs
Imugene Limited
Imugene Limited Australia

Bringing Effective New Treatments And Options To Patients Who Need Them

IPO
29 employees
Biotechnology, Health Care
IOME BIO vs
OncoResponse
OncoResponse United States

Interrogating for Cures

10 employees
Biopharma, Biotechnology
View all alternatives

FAQ About IOME BIO

Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology
IOME BIO was founded in 2020.
IOME BIO is headquartered in France.
IOME BIO operates in Biotechnology, Health Care and Life Sciences. Its work centres on microbiome insights, immuno-oncology, PD/L-1 therapies and cancer treatment.
IOME BIO has approximately 4 employees.
Top alternatives and competitors to IOME BIO include Farcast Biosciences, Imugene Limited, OncoResponse, GamaMabs Pharma, ImmunoBiochem Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IOME BIO and Farcast Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for IOME BIO, https://bouncewatch.com/company/iome-bio, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes